TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Rhea-AI Summary

TransMedics (Nasdaq: TMDX) entered a definitive agreement to invest in Germany-based PAD Aviation to support creation of a dedicated organ transplant air and ground logistics network across Europe.

The proposed investment aims to replicate TransMedics' U.S. NOP logistics model, support the OCS perfusion platform and clinical services, and expand access to donor organs. Closing is expected later in 2026 and is subject to customary closing and regulatory conditions; financial terms were not disclosed.

AI-generated analysis. Not financial advice.

Positive

• Definitive agreement to invest in PAD Aviation to build European transplant logistics network
• Planned replication of U.S. NOP logistics model to support OCS perfusion platform and clinical services
• Company expects to expand organ access and transplant volumes across Europe over time

Negative

• Transaction is subject to closing and applicable regulatory conditions and may not complete in 2026
• Financial terms of the investment were not disclosed, limiting visibility on capital impact

News Market Reaction – TMDX

-2.66%

1 alert

-2.66% News Effect

On the day this news was published, TMDX declined 2.66%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Expected close timing: 2026

1 metrics

Expected close timing 2026 Company expects PAD Aviation transaction to close later in 2026

Market Reality Check

Price: $63.93 Vol: Volume 1,930,407 is 2.24x...

high vol

$63.93 Last Close

Volume Volume 1,930,407 is 2.24x the 20-day average of 860,650, indicating unusually heavy trading ahead of/around this announcement. high

Technical Shares trade below the 200-day MA, at 101.26 vs 200-day MA of 122.82, and sit 35.09% below the 52-week high of 156.

Peers on Argus

TMDX fell 6.34%, while key medical device peers like ITGR, GKOS, BRKR, INSP, and...

TMDX fell 6.34%, while key medical device peers like ITGR, GKOS, BRKR, INSP, and LIVN also declined but more moderately (moves from about -0.13% to -3.68%). The steeper drop in TMDX versus peers suggests a company-specific reaction rather than a broad sector move.

Common Catalyst Two peers (ITGR, INSP) reported participation in a Bank of America healthcare conference, pointing to typical conference-related news rather than a shared catalyst tied to transplant logistics.

Historical Context

5 past events · Latest: Apr 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 23	Clinical program update	Positive	-1.3%	Unveiled CHOPS system and highlighted FDA-approved ENHANCE Heart and DENOVO Lung trials.
Apr 21	Earnings date notice	Neutral	+4.0%	Announced timing and call details for Q1 2026 financial results release.
Feb 27	Tax allowance update	Positive	+7.9%	Explained $103.3M tax valuation allowance release and impact on Q4 2025 results.
Feb 24	Earnings report	Positive	-4.3%	Reported strong Q4 and FY 2025 growth, OCS case volume gains, and 2026 guidance.
Feb 20	Inducement grants	Neutral	+0.3%	Disclosed option and RSU inducement grants to new employees under Nasdaq rules.

Pattern Detected

Recent history shows mixed alignment: strong fundamental or clinical updates have sometimes been followed by downside (e.g., Q4/FY 2025 earnings), while tax and accounting clarification produced a strong positive move. Overall, reactions to news have been inconsistent, with both aligned and divergent moves around earnings and program updates.

Recent Company History

Over the last several months, TransMedics reported strong 2025 results with Q4 revenue $160.8M (+32% YoY), FY revenue $605.5M (+37% YoY), and 5,139 U.S. OCS cases alongside ownership of 22 aircraft and 2026 revenue guidance of $727M–$757M. A separate update detailed a $103.3M tax valuation allowance release and related $83.8M tax benefit, which saw shares rise 7.94%. Clinical momentum has continued with the CHOPS preservation system and FDA IDE approvals, though that news saw a modest -1.26% reaction. Today’s European logistics initiative builds on this integrated logistics and clinical platform narrative.

Market Pulse Summary

This announcement outlines TransMedics’ plan to invest in PAD Aviation to build a dedicated European...

Analysis

This announcement outlines TransMedics’ plan to invest in PAD Aviation to build a dedicated European transplant logistics network supporting its OCS platform. It extends the integrated technology-and-logistics model that underpinned $605.5M in 2025 revenue and expanding OCS case volume. Investors may focus on regulatory closing conditions, execution risks in new geographies, and how this initiative interacts with ongoing clinical programs and logistics assets, such as the company’s fleet of 22 aircraft highlighted in earlier disclosures.

Key Terms

perfusion, definitive agreement

2 terms

perfusion medical

"in support of its OCS™ perfusion platform and clinical services"

Perfusion is the flow of blood through a tissue or organ, delivering oxygen and nutrients and removing waste so cells can function. For investors, perfusion matters because devices, drugs and diagnostics that improve or measure blood flow can change treatment outcomes and market demand—think of it like irrigation for a garden: poor flow harms health, good flow supports recovery and value.

definitive agreement financial

"today announced that it has entered into a definitive agreement to invest"

A definitive agreement is a formal, legally binding document that outlines the final terms and conditions of a deal or transaction, such as a sale or partnership. It acts like a detailed contract that confirms all parties have agreed on the key details, making the deal official. For investors, it signals that the agreement is settled and moving toward completion, providing clarity and security about the transaction.

AI-generated analysis. Not financial advice.

Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe

ANDOVER, Mass., April 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator.

The proposed strategic investment is intended to support TransMedics' ongoing efforts to replicate the successful U.S. NOP and logistics model by building a dedicated organ transplantation air and ground logistics network in Europe in support of its OCS™ perfusion platform and clinical services, with the goal of expanding access to donor organs and increasing transplant volumes for patients in need across the European Union.

"Building a dedicated transplant air logistics network in Europe is a necessary first step to supporting our European NOP strategy to bring the full benefits of our OCS technology and integrated logistics model to European patients in need of transplantation. We are already actively building our presence in Italy and our sights are set on expanding access to donor organs and increasing transplant volumes for patients across Europe over time. We look forward to working with the PAD team to advance this vision over the years ahead," said Waleed Hassanein, M.D., President and Chief Executive Officer of TransMedics.

The proposed strategic investment is subject to the satisfaction of closing conditions specified in the definitive agreement between the parties (the "Agreement") as well as applicable regulatory conditions. TransMedics expects the transaction to close later in 2026 but can provide no assurance that the proposed transaction will be consummated. Financial terms are not being disclosed.

About PAD Aviation service GmbH
PAD Aviation is a leading European business aviation operator, independent of commercial airlines. The company operates from its 24/7 hub in Paderborn, Germany, offering maximum flexibility—particularly for time-critical missions such as organ transport. From its centrally located base, PAD Aviation's aircraft can rapidly reach destinations across Europe. The company operates a modern fleet, including nine Embraer Phenom 300 aircraft, and employs more than 40 highly trained and type-rated pilots. PAD Aviation holds a valid EASA Air Operator Certificate (AOC).

About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements address various matters, including, among other things, the proposed strategic investment in PAD Aviation pursuant to the Agreement and the expected timing and consummation thereof; the anticipated benefits of the proposed strategic investment, including the establishment of dedicated air logistics infrastructure to support the OCS and NOP platforms in the European Union; our strategy of replicating our U.S. NOP model in Europe, including through dedicated air and ground logistics; the expected role of the aviation licensing, certifications, and operational infrastructure in supporting the European NOP; our ongoing commercial operations in Italy; and our broader international expansion plans and the costs related thereto. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are subject to a number of risks and uncertainties. Management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: risks and uncertainties related to the pending strategic investment in PAD Aviation, including the occurrence of any event, change or other circumstance that could give rise to the termination of the Agreement; the risk that conditions to closing of the transaction are not obtained in a timely manner or at all; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees, other business partners or governmental entities; transaction costs; the risk that the transaction will divert management's attention from TransMedics' ongoing business operations or otherwise disrupts TransMedics' ongoing business operations; risks related to the ability to integrate PAD Aviation with TransMedics, including retaining key employees; risks related to operating an aviation business; risks related to the ability to further grow and enhance the National OCS Program; and other factors described in TransMedics' filings with the Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in TransMedics' Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, and comparable disclosure in our subsequent filings with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Investor Contact:
Brian Johnston
Gilmartin Group
Investors@transmedics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-group-announces-intent-to-create-the-first-dedicated-european-transplant-logistics-network-with-strategic-investment-in-pad-aviation-service-gmbh-302757305.html

SOURCE TransMedics Group, Inc.

FAQ

What did TransMedics (TMDX) announce about PAD Aviation on April 29, 2026?

They entered a definitive agreement to invest in PAD Aviation to build a European transplant logistics network. According to the company, the investment aims to support creation of air and ground logistics for the OCS perfusion platform and clinical services.

When does TransMedics expect the PAD Aviation investment to close for TMDX shareholders?

TransMedics expects the transaction to close later in 2026 but provided no assurance it will complete. According to the company, closing remains subject to specified agreement conditions and applicable regulatory approvals.

How will the PAD Aviation deal affect TransMedics' (TMDX) European transplant strategy?

The investment is intended to establish a dedicated air and ground logistics network supporting the European NOP strategy. According to the company, this is designed to replicate the U.S. logistics model and support OCS operations and clinical services.

Did TransMedics disclose financial terms for the PAD Aviation investment (TMDX)?

No, TransMedics did not disclose financial terms for the proposed investment. According to the company, financial details remain undisclosed and the parties provided no capital or valuation figures in the announcement.

What regulatory or closing risks should investors consider for TMDX's PAD Aviation deal?

The deal is conditional on satisfaction of closing and applicable regulatory conditions, so it may not close as expected. According to the company, completion depends on those conditions and timing could shift or the transaction may not be consummated.